
Opinion|Videos|May 3, 2024
Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer
Author(s)Stephanie L. Graff, MD
An expert on breast cancer reviews currently available tests for ESR1 mutations and provides clinical insights on best practices for testing.
Advertisement
Episodes in this series

Advertisement
Related to this article

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."

The updated label now includes phase 3 data comparing aficamten monotherapy with metoprolol in adults with symptomatic obstructive HCM.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
3
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
4
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
5


